Цирротическая кардиомиопатия

Т.Г. Раевнева, Н.И. Артишевская, А.А. Савченко УО «Белорусский государственный медицинский университет»

2013 №3 | В помощь практикующему врачу

Аннотация

Список литературы

Среди заболеваний печени, формирующих осложнения со стороны сердечно-сосудистой системы, особое место занимает цирроз печени. С циррозом ассоциированы гепатопульмонарный синдром; портолегочная гипертензия; гидроперикард; цирротическая кардиомиопатия.

Ключевые слова:

цирроз печени, цирротическая кардиомиопатия

Tsirroticheskaya cardiomyopathy

Among the diseases of the liver, forming the complications of the cardiovascular system, it occupies a special place cirrhosis. Gepatopulmonarny associated with cirrhosis of the syndrome; portopulmonary hypertension; hydropericardium; cirrhotic cardiomyopathy.

Keywords

cirrhosis, cirrhotic cardiomyopathy

1. Soon, K. Baik1, Tamer R Fouad, Samuel S Lee. Cirrhotic cardiomyopathy. Orphanet Journal of Rare Diseases.- 2007.- 2:15.-1750-1172.
2. Kowalski, HJ, Abelman WH. The cardiac output at rest in Laennec’s cirrhosis. J Clin Invest. 1953.- 32(10). Р.-1025–1033.
3. Abelmann, WH, Kowalski HJ, McNeely WF. The hemodynamic response to exercise in patients with Laennec’s cirrhosis. Clin Invest.- 1955.- 34.-Р.690-695.
4. Day, CP, James OF, Butler , Campbell RW. QT prolongation and sudden cardiac death in patients with alcoholic liver disease. Lancet.- 1993.- 5.-1423-1428.
5. Rayes, N, Bechstein WO, Keck H et all. Causes of death after liver transplantation: an analysis of 41 cases in 382 patients. Zentralblatt Chir 1995.-120.-P.435–438
6. Bernardi, M, Calandra S, Colantoni A et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology.1998.-27(1).- P.28-34.
7. Lee, SS. Cardiac abnormalities in liver cirrhosis. West J Med .- 1989.-151.-P. 530–539.
8. Laffi, G, Barletta G, La Villa G et al. Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis. Gastroenterology.- 1997.-113.-P. 891–898.
9. Wong, F, Girgrah N, Graba J et al. The effect of cirrhotic cardiomyopathy on the cardiac response to exercise in cirrhosis. Gut.- 2001.-49.-P.268–275.
10. Moreau, R, Hadengue A, Soupison T et al. Abnormal pressor response to vasopressin in patients with cirrhosis: evidence for impaired buffering mechanism. Hepatology.- 1990.-12.-P.7–12.
11. Wong, F, Liu P, Lilly L et al. The role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci.- 1999.-97. P.259–267.
12. Møller, S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut.- 2008.-57.- P. 268–278.
13. Xiao, RP, Cheng H, Zhou YY et al. Recent advances in cardiac beta-adrenergic signal transduction. Circ Res. – 1999.-85.-P.1092–1100.
14. Alqahtani, SA, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Sem Liver Dis.- 2008.-28.-P.59–69.
15. Ward, C.A., Ma Z., Lee S.S. et al. Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis.Am J Physiol.- 1997.-273.-P. 537-544.
16. Ma Z, Lee SS, Meddings JB. Effects of altered cardiac membrane fluidity on beta-adrenergic receptor signalling in rats with cirrhotic cardiomyopathy. J Hepatol.- 1997.-26.-P.904–912.
17. Ma, Z, Miyamoto A, Lee SS. Role of altered betaadrenoreceptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats. Gastroenterology 1996.- 110.-P.1191–1198.
18. Devane, W.A. ,Miyamoto A, Lee SS.et al. Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology. 1988.- 34(5).-P.605-613.
19. Caraceni, P, Domenicali M, Bernardi M. The endocannabinoid system and liver diseases. J Neuroendocrinol.- 2008.-20.-P.47–52.
20. Gaskari, SE, Liu H, Moezi L et al. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct ligated rats. Br J Pharmacol.- 2005.-146.-P.315–323.
21. Batkai, S, Mukhopadhyay P, Harvey-White J et al. Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol Heart Circ Physiol.-2007.-293.-P.1689–1695.
22. Liu, H, Ma Z, Lee SS. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Gastroenterology.- 2000.-118.-P. 937–944.
23. Liu, H, Song D, Lee SS. Role of heme oxygenase-carbon monoxide pathway in pathogenesis of cirrhotic cardiomyopathy in the rat. Am J Physiol Gastrointest Liver Physiol.- 2001.-280.-P.68–74.
24. Liu, H, Lee SS. Nuclear factor-kappa B inhibition improves myocardial contractility in rats with cirrhotic cardiomyopathy. Liver Int.- 2008.-28.-P.640–648.
25. Lin, RS, Lee FY, Lee SD et al. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol.- 1995.-22.-P.165–172.
26. Ma, Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology.- 1996.- 24.- P.451-459.
27. Liu, H, Lee SS. Cardiopulmonary dysfunction in cirrhosis. J Gastroenterol Hepatol.- 1999.- 14.-P.600-608.
28. Zhong, J, Hwang TC, Adams HR et al. Reduced L-type calcium current in ventricular myocytes from endotoxemic guinea pigs. Am J Physiol.- 1997.- 273.-P.2312–2324.
29. Gould, L, Shariff M, Zahir M et al. Cardiac hemodynamics in alcoholic patients with chronic liver disease and a presystolic gallop. J Clin Invest.- 1969.-48.-P. 860–868
30. Kelbaek, H, Eriksen J, Brynjolf I et al. Cardiac performance in patients with asymptomatic alcoholic cirrhosis of the liver. Am J Cardiol.- 1984.-54.-P.852–855.
31. Ruiz-del-Arbol, L, Urman J, Fernandez J et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology.- 2003.-38.-P.1210–1218.
32. Ruiz-del-Arbol, L, Monescillo A, Arocena C et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology.- 2005.-42. – P.439–447.
33. Bernardi, M, Rubboli A, Trevisani F et al. Reduced cardiovascular responsiveness to exercise-induced sympathoadrenergic stimulation in patients with cirrhosis. J Hepatology.- 1991.-12.-P.207–216.
34. F Wong, P Liu, L Blendis. Sodium homeostasis with chronic sodium loading in preascitic cirrhosis. Gut.- 2001.-49.-P.847–851.
35. Pozzi, M, Grassi G, Ratti et al. Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child A cirrhosis. Am J Gastroenterol.- 2005.-100.-P. 1110–1116.
36. Pitt, B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med.- 1999.-341.-P.709–717.